Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 952-958

  Tantishaiyakul, Vimon ^a   Suknuntha, Krit ^a   Vao Soongnern, Visit ^b  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b SURANAREE UNIVERSITY OF TECHNOLOGY   (Thailand)

Author keywords

13C CP MAS NMR; Cimetidine; Molecular dynamics; Piroxicam; X ray powder diffractometry

Indexed keywords

AMIDE; CARBON 11; CARBON 13; CIMETIDINE; HYDROGEN; NITROGEN; OXYGEN; PIROXICAM; ANTIULCER AGENT; DRUG COMBINATION; DRUG MIXTURE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; ATOM; CRYSTAL STRUCTURE; DRUG CONFORMATION; EXPERIMENTAL STUDY; INFRARED SPECTROSCOPY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE; POWDER; PRECIPITATION; PRIORITY JOURNAL; SIMULATION; SOLID STATE; STRETCHING; CHEMICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DRUG COMBINATION; DRUG FORMULATION; DRUG MIXTURE; PROCEDURES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CHEMICAL PRECIPITATION; CIMETIDINE; COMPLEX MIXTURES; COMPUTER SIMULATION; DRUG COMBINATIONS; DRUG COMPOUNDING; MODELS, CHEMICAL;

EID: 77954815697     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9461-5     Document Type: Article

References (44)

1. Morre DJ, Morre DM. tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS). Mol Cell Biochem. 2006;283:159-67.
2. Knottenbelt C, Chambers G, Gault E, Argyle DJ. The in vitro effects of piroxicam and meloxicam on canine cell lines. J Small Anim Pract. 2006;47:14-20.
3. Semble EL, Wu WC. Antiinflammatory drugs and gastric mucosal damage. Semin Arthritis Rheum. 1987;16:271-86.
4. Finkelstein W, Isselbacher KJ. Drug therapy: cimetidine. N Engl J Med. 1978;299:992-6.
5. Maciel HP, Cardoso LG, Ferreira LR, Perazzo FF, Carvalho JC. Anti-inflammatory and ulcerogenic effects of indomethacin and tenoxicam in combination with cimetidine. Inflammopharmacol. 2004;12:203-10.
6. Takahashi HK, Watanabe T, Yokoyama A, Iwagaki H, Yoshino T, Tanaka N, et al. Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006;70:450-3.
7. Lefranc F, Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review). Int J Oncol. 2006;28:1021-30.
8. Milligan PA, McGill PE, Howden CW, Kelman AW, Whiting B. The consequences of H2 receptor antagonist-piroxicam coadministration in patients with joint disorders. Eur J Clin Pharmacol. 1993;45:507-12.
9. Said SA, Foda AM. Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. Arzneimittelforschung. 1989;39:790-2.
10. Guo W, Hamilton JA. Phase behavior and crystalline structures of cholesteryl ester mixtures:A C-13 MASNMR study. Biophys J. 1995;68:2376-86.
11. Yamamura S, Gotoh H, Sakamoto Y, Momose Y. Physicochemical properties of amorphous salt of cimetidine and diflunisal system. Int J Pharm. 2002;241:213-21.
12. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17:397-404.
13. Liu J, Qiu L, Gao J, Jin Y. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropylbeta-cyclodextrin. Int J Pharm. 2006;312:137-43.
14. Zmitek J, Smidovnik A, Fir M, Prosek M, Zmitek K, Walczak J, et al. Relative bioavailability of two forms of a novel watersoluble coenzyme Q10. Ann Nutr Metab. 2008;52:281-7.
15. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone K-30. Int J Pharm. 1996;143:59-66.
16. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm. 1999;181:143-51.
17. Valizadeh H, Zakeri-Milani P, Barzegar-Jalali M, Mohammadi G, Danesh-Bahreini MA, Adibkia K, et al. Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev Ind Pharm. 2007;33:45-56.
18. Redenti E, Zanol M, Ventura P, Fronza G, Comotti A, Taddei P, et al. Raman and solid state 13C-NMR investigation of the structure of the 1:1 amorphous piroxicam:β-cyclodextrin inclusion compound. Biospectroscopy. 1999;5:243-51.
19. Tantishaiyakul V, Songkro S, Suknuntha K, Permkum P, Pipatwarakul P. Crystal structure transformations and dissolution studies of cimetidine-piroxicam coprecipitates and physical mixtures. AAPS PharmSciTech. 2009;10:789-95.
20. Okonogi S, Puttipipatkhachorn S. Dissolution improvement of high drug-loaded solid dispersion. AAPS PharmSciTech. 2006;7: E1-6.
21. Mashru RC, Sutariya VB, Sankalia MG, Yagnakumar P. Characterization of solid dispersions of rofecoxib using differential scanning calorimeter. JTherm Anal Calorim. 2005;82:167-70.
22. Schachter DM, Xiong J, Tirol GC. Solid state NMR perspective of drug-polymer solid solutions: a model system based on poly (ethylene oxide). Int J Pharm. 2004;281:89-101.
23. Suknuntha K, Tantishaiyakul V, Vao-Soongnern V, Espidel Y, Cosgrove T. Molecular modeling simulation and experimental measurements to characterize chitosan and poly (vinyl pyrrolidone) blend interactions. J Polym Sci Polym Phys. 2008;46:1258-64.
24. Sandoval C, Castro C, Gargallo L, Radic D, Freire J. Specific interactions in blends containing chitosan and functionalized polymers. Molecular dynamics simulations. Polymer. 2005;46:10437-42.
25. Suga Y, Takahama T. Application of molecular simulation to prediction of solubility parameter. Chem Lett. 1996;281-2.
26. Jacobson SH. Molecular modeling studies of polymeric transdermal adhesives: structure and transport mechanisms. Pharm Technol. 1999;122-30.
27. Li B, Pan F, Fang Z, Liu L, Jiang Z. Molecular dynamics simulation of diffusion behavior of benzene/water in PDMS-calix [4] arene hybrid pervaporation membranes. Ind Eng Chem Res. 2008;47:4440-7.
28. Heuchel M, Hofmann D, Pullumbi P. Molecular modeling of small-molecule permeation in polyimides and its correlation to free-volume distributions. Macromolecules. 2004;37:201-14.
29. Vrecer F, Vrbinc M, Meden A. Characterization of piroxicam crystal modifications. Int J Pharm. 2003;256:3-15.
30. Sheth AR, Bates S, Muller FX, Grant D J W. Polymorphism in piroxicam. Cryst Growth Des. 2004;4:1091-8.
31. Baranska M, Proniewicz LM. FT-IR and FT-Raman spectra of cimetidine and its metallocomplexes. J Mol Struct. 1999;511-512:153-62.
32. Shibata M, Kokubo H, Morimoto K, Morisaka K, Ishida T, Inoue M. X-ray structural studies and physicochemical properties of cimetidine polymorphism. J Pharm Sci. 1983;72:1436-42.
33. Sheth AR, Bates S, Muller FX, Grant D J W. Local structure in amorphous phases of piroxicam from powder X-ray diffractometry. Cryst Growth Des. 2005;5:571-8.
34. Rigby D. Fluid density predictions using the COMPASS force field. Fluid Phase Equilib. 2004;217:77-87.
35. Mazeau K, Heux L. Molecular dynamics simulations of bulk native crystalline and amorphous structures of cellulose. J Phys Chem B. 2003;107:2394-403.
36. Tantishaiyakul V, Permkam P, Suknuntha K. Use of DRIFTS and PLS for the determination of polymorphs of piroxicam alone and in combination with pharmaceutical excipients: a technical note. AAPS PharmSciTech. 2008;9:95-9.
37. Hegedus B, Gorog S. The polymorphism of cimetidine. J Pharm Biomed Anal. 1985;3:303-13.
38. Middleton DA, Duff C S L, Berst F, Reid DG. A cross-polarization magic-angle spinning 13C NMR characterization of the stable solid-state forms of cimetidine. J Pharm Sci. 1997;86:1400-2.
39. Sheth AR, Lubach JW, Munson EJ, Muller FX, Grant D J W. Mechanochromism of piroxicam accompanied by intermolecular proton transfer probed by spectroscopic methods and solid-phase changes. J Am Chem Soc. 2005;127:6641-51.
40. Geckle JM, Rescek DM, Whipple EB. Zwitterionic piroxicam in polar solution. Magn Reson Chem. 1989;27:150-4.
41. Karpinska G, Dobrowolski JC, Mazurek AP. Conformation and tautomerism of the cimetidine molecule: a theoretical study. J Mol Struct. 2003;645:37-43.
42. Taddei P, Torreggiani A, Simoni R. Influence of environment on piroxicam polymorphism: vibrational spectroscopic study. Biopolymers. 2000;62:68-78.
43. 13C solid-state NMR distance and angle measurements. J Am Chem Soc. 2000;122:1161-70.
44. Birkedal H, Bauer-Brandl A, Pattison P. The surprising polymorph C of cimetidine: synchrotron radiation to the rescue. XIXth European Crystallographic Meeting. Nancy, France: Abstracts. Acta Cryst. 2000; A56: s337. Supplement.